Introduction Previous studies have shown an association between gout and/or
hyperuricemia and a subsequent increase in cardiovascular disease (CVD) outcomes …

Gout is caused by monosodium urate crystal deposition in joints and tissues. Risk factors
include male sex; obesity; hypertension; alcohol intake; diuretic use; a diet rich in meat and …

Background: Febuxostat, a nonpurine selective inhibitor of both the oxidized and reduced
forms of xanthine oxidase, was approved in February 2009 by the US Food and Drug …

Objectives. This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-
term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction …

Objective. To determine longterm urate-lowering efficacy and clinical benefits and safety of
therapy with febuxostat or allopurinol in subjects with gout. Methods. Subjects (n= 1086) in …

Background: Patients with gout are at an increased risk of cardiovascular (CV) disease
including myocardial infarction (MI), stroke, and heart failure (HF). Objectives: The authors …

Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV)
disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a …

Background New drugs and new evidence concerning the use of established treatments
have become available since the publication of the first European League Against …

Objective: To review the pharmacology, pharmacokinetics, clinical trial data, safety profile,
precautions, and place in therapy of febuxostat, a novel nonpurine xanthine oxidase …

Objectives: To investigate the efficacy and tolerability of allopurinol as the first-choice
antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of …